Skip to main content
. 2012 Aug 17;38(5):958–966. doi: 10.1093/schbul/sbs069

Fig. 3.

Fig. 3.

Effect of NMDAR glycine-site agonists on motor symptoms (tardive dyskinesia) as reflected in Abnormal Involuntary Movement Scale (AIMS) score. Data are from studies of glycine 74 75 or D-serine. 76 77 Across all studies, D-serine treatment led to a highly significant (t = 4.86, df = 192, P < .00001, d = .83) improvement in AIMS symptom, suggesting benefit of NMDAR agonist on motor and neuropsychological symptoms in schizophrenia.